Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma

Lapo Alinari, Gerardo Musuraca, Monica Tani, Vittorio Stefoni, Annalisa Gabriele, Enrica Marchi, Mariapaola Fina, Antonio de Vivo, Stefano Pileri, Michele Baccarani, Peter Luigi Zinzani

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In order to assess the efficacy and toxicity profile of oxaliplatin, a third generation platinum derivate active against several solid tumors, we carried out a study in a group of heavily pretreated patients with non-Hodgkin's lymphoma (NHL). Between August 2003 and May 2004, 19 pretreated patients were enrolled in a phase II trial and were treated with oxaliplatin. The drug was administered intravenously on day 1 of a 21-day schedule, at a dose of 130 mg/m2 for a total of 6 cycles. One (5%) patient achieved complete remission (CR) and 5 patients (27%) had partial response (PR), thus giving an overall response rate of 32%. The patient in CR suffered from an aggressive B NHL. One of the 5 patients in PR had an aggressive B NHL, whereas the remaining 4 had an indolent B NHL. The treatment was well tolerated with minimal hematologic and extrahematologic toxicity. These data suggest and confirm the efficacy and low toxicity of oxaliplatin in the treatment of patients with heavily pretreated NHL. Further trials using oxaliplatin alone or in combination with other conventional drugs are needed.

Original languageEnglish
Pages (from-to)1437-1440
Number of pages4
JournalLeukemia and Lymphoma
Volume46
Issue number10
DOIs
Publication statusPublished - Oct 2005

Fingerprint

oxaliplatin
Non-Hodgkin's Lymphoma
Therapeutics
Platinum
Pharmaceutical Preparations

Keywords

  • Chemotherapy
  • Non-Hodgkin's lymphoma
  • Oxaliplatin
  • Pretreated

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Alinari, L., Musuraca, G., Tani, M., Stefoni, V., Gabriele, A., Marchi, E., ... Zinzani, P. L. (2005). Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. Leukemia and Lymphoma, 46(10), 1437-1440. https://doi.org/10.1080/10428190500178779

Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. / Alinari, Lapo; Musuraca, Gerardo; Tani, Monica; Stefoni, Vittorio; Gabriele, Annalisa; Marchi, Enrica; Fina, Mariapaola; de Vivo, Antonio; Pileri, Stefano; Baccarani, Michele; Zinzani, Peter Luigi.

In: Leukemia and Lymphoma, Vol. 46, No. 10, 10.2005, p. 1437-1440.

Research output: Contribution to journalArticle

Alinari, L, Musuraca, G, Tani, M, Stefoni, V, Gabriele, A, Marchi, E, Fina, M, de Vivo, A, Pileri, S, Baccarani, M & Zinzani, PL 2005, 'Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma', Leukemia and Lymphoma, vol. 46, no. 10, pp. 1437-1440. https://doi.org/10.1080/10428190500178779
Alinari, Lapo ; Musuraca, Gerardo ; Tani, Monica ; Stefoni, Vittorio ; Gabriele, Annalisa ; Marchi, Enrica ; Fina, Mariapaola ; de Vivo, Antonio ; Pileri, Stefano ; Baccarani, Michele ; Zinzani, Peter Luigi. / Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. In: Leukemia and Lymphoma. 2005 ; Vol. 46, No. 10. pp. 1437-1440.
@article{886c3fb43ab34297ad974075501b7d2b,
title = "Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma",
abstract = "In order to assess the efficacy and toxicity profile of oxaliplatin, a third generation platinum derivate active against several solid tumors, we carried out a study in a group of heavily pretreated patients with non-Hodgkin's lymphoma (NHL). Between August 2003 and May 2004, 19 pretreated patients were enrolled in a phase II trial and were treated with oxaliplatin. The drug was administered intravenously on day 1 of a 21-day schedule, at a dose of 130 mg/m2 for a total of 6 cycles. One (5{\%}) patient achieved complete remission (CR) and 5 patients (27{\%}) had partial response (PR), thus giving an overall response rate of 32{\%}. The patient in CR suffered from an aggressive B NHL. One of the 5 patients in PR had an aggressive B NHL, whereas the remaining 4 had an indolent B NHL. The treatment was well tolerated with minimal hematologic and extrahematologic toxicity. These data suggest and confirm the efficacy and low toxicity of oxaliplatin in the treatment of patients with heavily pretreated NHL. Further trials using oxaliplatin alone or in combination with other conventional drugs are needed.",
keywords = "Chemotherapy, Non-Hodgkin's lymphoma, Oxaliplatin, Pretreated",
author = "Lapo Alinari and Gerardo Musuraca and Monica Tani and Vittorio Stefoni and Annalisa Gabriele and Enrica Marchi and Mariapaola Fina and {de Vivo}, Antonio and Stefano Pileri and Michele Baccarani and Zinzani, {Peter Luigi}",
year = "2005",
month = "10",
doi = "10.1080/10428190500178779",
language = "English",
volume = "46",
pages = "1437--1440",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma

AU - Alinari, Lapo

AU - Musuraca, Gerardo

AU - Tani, Monica

AU - Stefoni, Vittorio

AU - Gabriele, Annalisa

AU - Marchi, Enrica

AU - Fina, Mariapaola

AU - de Vivo, Antonio

AU - Pileri, Stefano

AU - Baccarani, Michele

AU - Zinzani, Peter Luigi

PY - 2005/10

Y1 - 2005/10

N2 - In order to assess the efficacy and toxicity profile of oxaliplatin, a third generation platinum derivate active against several solid tumors, we carried out a study in a group of heavily pretreated patients with non-Hodgkin's lymphoma (NHL). Between August 2003 and May 2004, 19 pretreated patients were enrolled in a phase II trial and were treated with oxaliplatin. The drug was administered intravenously on day 1 of a 21-day schedule, at a dose of 130 mg/m2 for a total of 6 cycles. One (5%) patient achieved complete remission (CR) and 5 patients (27%) had partial response (PR), thus giving an overall response rate of 32%. The patient in CR suffered from an aggressive B NHL. One of the 5 patients in PR had an aggressive B NHL, whereas the remaining 4 had an indolent B NHL. The treatment was well tolerated with minimal hematologic and extrahematologic toxicity. These data suggest and confirm the efficacy and low toxicity of oxaliplatin in the treatment of patients with heavily pretreated NHL. Further trials using oxaliplatin alone or in combination with other conventional drugs are needed.

AB - In order to assess the efficacy and toxicity profile of oxaliplatin, a third generation platinum derivate active against several solid tumors, we carried out a study in a group of heavily pretreated patients with non-Hodgkin's lymphoma (NHL). Between August 2003 and May 2004, 19 pretreated patients were enrolled in a phase II trial and were treated with oxaliplatin. The drug was administered intravenously on day 1 of a 21-day schedule, at a dose of 130 mg/m2 for a total of 6 cycles. One (5%) patient achieved complete remission (CR) and 5 patients (27%) had partial response (PR), thus giving an overall response rate of 32%. The patient in CR suffered from an aggressive B NHL. One of the 5 patients in PR had an aggressive B NHL, whereas the remaining 4 had an indolent B NHL. The treatment was well tolerated with minimal hematologic and extrahematologic toxicity. These data suggest and confirm the efficacy and low toxicity of oxaliplatin in the treatment of patients with heavily pretreated NHL. Further trials using oxaliplatin alone or in combination with other conventional drugs are needed.

KW - Chemotherapy

KW - Non-Hodgkin's lymphoma

KW - Oxaliplatin

KW - Pretreated

UR - http://www.scopus.com/inward/record.url?scp=26944499050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944499050&partnerID=8YFLogxK

U2 - 10.1080/10428190500178779

DO - 10.1080/10428190500178779

M3 - Article

VL - 46

SP - 1437

EP - 1440

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -